Xenon Pharmaceuticals May Have A Blockbuster Drug In Store, BofA Says

Xenon Pharmaceuticals Inc’s XENE epilepsy candidate, XEN1101, is currently in phase III trials and “looks poised to be a blockbuster,” according to BofA Securities.

The Xenon Pharmaceuticals Analyst: Jason Gerberry initiated coverage of Xenon Pharmaceuticals with a Buy rating and a price target of $48.

The Xenon Pharmaceuticals Thesis: Results from the phase III trials should match or beat the first readout, Gerberry said in the initiation note.

Check out other analyst stock ratings.

XEN1101 has a “differentiated product profile,” with strong early anti-seizure data and simplicity of dosing, which positions it as a potential blockbuster anti-seizure medication, he added.

“We see ‘1101 as closer to Vimpat as a launch-analog (nearly $2bn peak sales) given potential to widely be used as 3L/4L SOC (third line and fourth line standard of care) with upside if broader benefits (broader spectrum ASM or improving mood) are confirmed in future trials,” the analyst wrote.

Also Read: Bed Bath & Beyond Stock Pops Ahead Of Strategic Update: What Investors Need To Know

XENE Price Action: Shares of Xenon Pharmaceuticals were up 2.14% to $37.76 at the time of publication on Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorInitiationAnalyst RatingsBofA SecuritiesJason Gerberry
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!